ClinicalTrials.gg
Enrolling by invitationNCT05441696Updated Dec 27, 2024

Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients

An observational study in Congestive Heart Failure, sponsored by Nihon Kohden. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Nihon Kohden · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
65
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
350th of 552
65 · median 150
Started
2022
with 106 others
Observational
553 of 2,159
102 open now
Primary completion
2025-09
later than 51 of 438 live
Registered
1,698th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 350th largest by planned enrollment of the 552 observational ones that give a count, is one of 107 that started in 2022, is one of 553 observational ones, reaches primary completion later than 51 of the 438 other live ones, and was the 1,698th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

Track changes in non-invasive central venous pressure across hospital stay and relationship with readmission

Read the detailed description

Determining the degree of congestion is important in deciding appropriate timing for discharging hospitalized heart failure patients. Central venous pressure (CVP) reflects the returning blood volume to the heart and can guide therapy to relieve congestion. However, the conventional method used to measure CVP has notable limitations as it is an invasive procedure that requires placement of a central venous catheter.

Traditional, non-invasive methods of estimating CVP, such as physical examination and echocardiogram, are less accurate and more resource intensive. To overcome this challenge, new technology to assess CVP non-invasively using an oscillometric method has been developed. This new technology involves measurement of the enclosed zone central venous pressure (ezCVP), which, in a preclinical study, has been shown to correlate with invasive data.

Additionally, a previous correlation study demonstrated that the ezCVP value can be mathematically adjusted to estimate invasive CVP. The resulting value has been termed CVPNI (CVP Non-Invasive). Most recently, a limited pilot study of patients hospitalized with acute, decompensated heart failure demonstrated the feasibility of device use in this population and the expected and incremental fall in CVPNI with medical treatment over the course of hospitalization.

Moving forward, and in order to further improve the care of patients hospitalized with heart failure, an expanded pilot study of ezCVP technology is needed to prove that changes in CVPNI track with these patients' condition during admission and can be useful in their clinical care.

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects admitted due to heart failure exacerbation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Arm circumference of 23 cm to 55 cm
  • Subject admitted to the hospital with acute exacerbation of heart failure, with either reduced or preserved
  • Subject is at risk for readmission ( Functional Classification 2-3)
  • Subject is able to understand the risks and potential benefits of participating in the study and is willing to provide written,
  • ezCVP indicator is high (CVPNI is over 9 mmHg) at admission
  • Subject is willing and able to comply with protocol procedures
  • Subject tested negative for COVID test after admission to the hospital

Exclusion criteria

Exclusion Criteria:

  • Finger and upper arm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor and/or blood pressure cuff
  • Pregnant (self-reported)
  • Upper extremity DVT (currently being treated)
  • Severe skin disease involving the upper arm(s)
  • Study investigator may exclude patients based on clinical judgement
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
65 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult CHF subjects with initial high CVP

    Adult subjects with congestive heart failure diagnosis who have an indicated high non-invasive estimated central venous pressure on first measurement after clinical unit admission.

    Device: ezCVP measurement

  • Adult CHF subjects with initial low CVP

    Adult subjects with congestive heart failure diagnosis who have an indicated low non-invasive estimated central venous pressure on first measurement after clinical unit admission.

    Device: ezCVP measurement

Interventions

  • DeviceezCVP measurement

    * Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP. * Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US). * Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan).

06

What researchers measure

Primary outcomes

  1. Evaluate the difference between non-invasive CVP measurement at admission and at discharge

    Compare CVPNI at time of admission and discharge in clinical unit CVPNI (CVP subscript NI) is a numeric value equivalence of central venous pressure non-invasive measured in mmHg.

    Time frame: 7 days

  2. Evaluate the difference between non-invasive CVP measurement in right and left arms

    Compare CVPNI (mmHg) for measurements on left and right arm for same subject

    Time frame: 7 days

Secondary outcomes

  1. Evaluate the relationship between CVPNI at discharge and readmission rate

    Compare CVPNI (mmHg) at time of discharge for high ezCVP subjects to subsequent readmission occurrence within 90-100 days post hospital discharge

    Time frame: 100 days

  2. Evaluate the relationship between CVPNI to clinical parameter weight during hospitalization

    Compare CVPNI changes (∆ mmHg) for high ezCVP subjects during hospitalization to change in measured weight (∆ g)

    Time frame: 7 days

  3. Compare changes in CVPNI to changes in KCCQ quality scores

    For each of the 3 Kansas City Cardiomyopathy Questionnaire (KCCQ) totals (integer number with no unit of measure): 1. Overall summary score; 2. clinical summary score; 3. symptom stability score: calculate: ∆KCCQ = KCCQ@14 days - KCCQ@admission. Count number of subjects in each group: ABSOLUTE(∆KCCQ) \< 6 (no significant change); ∆KCCQ \>= 6 (significant change improvement); ∆KCCQ \<= -6 (significant change worsening). Compare to ∆CVPNI (unit = mmHg) = CVPNI-mean@admission - CVPNI-mean@discharge. Count number of subjects in each group: ∆CVPNI \<= 0 (no improvement or worsening); ∆CVPNI \> 0 \& \< 5 (improvement); ∆CVPNI \> 5 (large improvement).

    Time frame: 21 days

  4. Evaluate the relationship between CVPNI and readmission rate for low and high ezCVP subjects

    Compare CVPNI at time of discharge for high ezCVP subjects versus low ezCVP subjects to subsequent readmission occurrence within 90-100 days post hospital discharge. Readmission is a binary value (true or false).

    Time frame: 100 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared. Aggregate results will be published by the investigators in academic journals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Sep 2025, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jul 1, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 29, 2026
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05441696
Lead sponsor
Nihon Kohden
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Jun 1, 2022
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 29, 2026 (estimated)
Last update
Dec 27, 2024

Study contacts

Masataka Kawana, MD
principal investigator · Stanford University
Patricia Nguyen, MD
principal investigator · Veterans Affairs Hospital Palo Alto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion